A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer

被引：13

作者：

Blanc-Durand, Felix ^{[1
]}

Yaniz-Galende, Elisa ^{[2
]}

Llop-Guevara, Alba ^{[3
]}

Genestie, Catherine ^{[4
]}

Serra, Violeta ^{[3
]}

Herencia-Ropero, Andrea ^{[3
]}

Klein, Christophe ^{[5
]}

Berton, Dominique ^{[6
,7
]}

Lortholary, Alain ^{[8
]}

Dohollou, Nadine ^{[9
]}

Desauw, Christophe ^{[10
]}

Fabbro, Michel ^{[11
]}

Malaurie, Emmanuelle

Bonichon-Lamaichhane, Nathalie

Dubot, Coraline ^{[12
]}

Kurtz, Jean Emmanuel

de Rauglaudre, Gaetan ^{[13
]}

Raban, Nadia

Chevalier-Place, Annick ^{[14
]}

Ferron, Gwenael ^{[15
]}

Kaminsky, Marie-Christine ^{[16
]}

Kramer, Claire

Rouleau, Etienne

Leary, Alexandra ^{[1
,2
,17
]}

机构：

[1] Gustave Roussy Inst, Gynecol Unit, Med Oncol, Villejuif, France

[2] Gustave Roussy Inst, INSERM UMR981, Villejuif, France

[3] Vall dHebron Inst Oncol, Expt Therapeut Grp, Barcelona, Spain

[4] Gustave Roussy Inst, Pathol Dept, Villejuif, France

[5] Cordeliers Res Ctr, Ctr Cellular Imaging & Cytometry, INSERM UMRS 1138, Paris, France

[6] GINECO, Med Oncol, St Herblain, France

[7] Inst Cancerol Ouest, St Herblain, France

[8] Hop Prive Confluent, Med Oncol, GINECO, Nantes, France

[9] Polyclin Bordeaux Nord Aquitain, Med Oncol, Bordeaux, France

[10] Ctr Hosp Univ, Med Oncol, Lille, France

[11] ICM Val dAurelle, Med Oncol, Montpellier, France

[12] Hop Rene Huguenin, Inst Curie, St Cloud, France

[13] Inst St Catherine, Avignon, France

[14] CHU Miletrie, Poitiers, France

[15] Inst Claudius Regaud, Toulouse, France

[16] Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France

[17] Inst Gustave Roussy, Med Oncol Dept, Gynecol Unit, Lead Translat Res Team,INSERM U981, 114 Rue Edouard Vaillant, F-94800 Villejuif, France

来源：

GYNECOLOGIC ONCOLOGY | 2023年 / 171卷

关键词：

Ovarian cancer; BRCA; EX-VIVO ASSAY; NEOADJUVANT CHEMOTHERAPY; PREDICTS RESPONSE; BEVACIZUMAB; SURVIVAL;

D O I：

10.1016/j.ygyno.2023.01.026

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Rationale. Homologous recombination deficiency (HRD), defined as BRCA1/2 mutation (BRCAmut) or high genomic instability, is used to identify ovarian cancer (OC) patients most likely to benefit from PARP inhibitors. While these tests are useful, they are imperfect. Another approach is to measure the capacity of tumor cells to form RAD51 foci in the presence of DNA damage using an immunofluorescence assay (IF). We aimed to describe for the first time this assay in OC and correlate it to platinum response and BRCAmut.Methods. Tumor samples were prospectively collected from the randomized CHIVA trial of neoadjuvant plat-inum +/- nintedanib. IF for RAD51, GMN and gH2AX was performed on FFPE blocks. Tumors were considered RAD51-low if <= 10% of GMN-positive tumor cells had >= 5 RAD51 foci. BRCAmut were identified by NGS.

引用

页码：106 / 113

页数：8

共 28 条

[1] Bray Freddie, 2018, CA Cancer J Clin, V68, P394, DOI [10.3322/caac.21609, 10.3322/caac.21492]
[2] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, Robert A.
Brady, Mark F.
Bookman, Michael A.
Fleming, Gini F.
Monk, Bradley J.
Huang, Helen
Mannel, Robert S.
Homesley, Howard D.
Fowler, Jeffrey
Greer, Benjamin E.
Boente, Matthew
Birrer, Michael J.
Liang, Sharon X.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) : 2473 - 2483
[3] Improved survival in women with BRCA-associated ovarian carcinoma
Cass, I
Baldwin, RL
Varkey, T
Moslehi, R
Narod, SA
Karlan, BY
[J]. CANCER, 2003, 97 (09) : 2187 - 2195
[4] A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Castroviejo-Bermejo, Marta
Cruz, Cristina
Llop-Guevara, Alba
Gutierrez-Enriquez, Sara
Ducy, Mandy
Hussein Ibrahim, Yasir
Gris-Oliver, Albert
Pellegrino, Benedetta
Bruna, Alejandra
Guzman, Marta
Rodriguez, Olga
Grueso, Judit
Bonache, Sandra
Moles-Fernandez, Alejandro
Villacampa, Guillermo
Viaplana, Cristina
Gomez, Patricia
Vidal, Marc
Peg, Vicente
Serres-Creixams, Xavier
Dellaire, Graham
Simard, Jacques
Nuciforo, Paolo
Rubio, Isabel T.
Dientsmann, Rodrigo
Barrett, J. Carl
Caldas, Carlos
Baselga, Jose
Saura, Cristina
Cortes, Javier
Deas, Olivier
Jonkers, Jos
Masson, Jean-Yves
Cairo, Stefano
Judde, Jean-Gabriel
O'Connor, Mark J.
Diez, Orland
Balmana, Judith
Serra, Violeta
[J]. EMBO MOLECULAR MEDICINE, 2018, 10 (12)
[5] RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
Cruz, C.
Castroviejo-Bermejo, M.
Gutierrez-Enriquez, S.
Llop-Guevara, A.
Ibrahim, Y. H.
Gris-Oliver, A.
Bonache, S.
Morancho, B.
Bruna, A.
Rueda, O. M.
Lai, Z.
Polanska, U. M.
Jones, G. N.
Kristel, P.
de Bustos, L.
Guzman, M.
Rodriguez, O.
Grueso, J.
Montalban, G.
Caratu, G.
Mancuso, F.
Fasani, R.
Jimenez, J.
Howat, W. J.
Dougherty, B.
Vivancos, A.
Nuciforo, P.
Serres-Creixams, X.
Rubio, I. T.
Oaknin, A.
Cadogan, E.
Barrett, J. C.
Caldas, C.
Baselga, J.
Saura, C.
Cortes, J.
Arribas, J.
Jonkers, J.
Diez, O.
O'Connor, M. J.
Balmana, J.
Serra, V
[J]. ANNALS OF ONCOLOGY, 2018, 29 (05) : 1203 - 1210
[6] Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas
de Jonge, Marthe M.
Auguste, Aurelie
van Wijk, Lise M.
Schouten, Philip C.
Meijers, Matty
ter Haar, Natalja T.
Smit, Vincent T. H. B. M.
Nout, Remi A.
Glaire, Mark A.
Church, David N.
Vrieling, Harry
Job, Bastien
Boursin, Yannick
de Kroon, Cor D.
Rouleau, Etienne
Leary, Alexandra
Vreeswijk, Maaike P. G.
Bosse, Tjalling
[J]. CLINICAL CANCER RESEARCH, 2019, 25 (03) : 1087 - 1097
[7] Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial
DiSilvestro, Paul
Colombo, Nicoletta
Scambia, Giovanni
Kim, Byoung-Gie
Oaknin, Ana
Friedlander, Michael
Lisyanskaya, Alla
Floquet, Anne
Leary, Alexandra
Sonke, Gabe S.
Gourley, Charlie
Banerjee, Susana
Oza, Amit
Gonzalez-Martin, Antonio
Aghajanian, Carol A.
Bradley, William H.
Mathews, Cara A.
Liu, Joyce
Lowe, Elizabeth S.
Bloomfield, Ralph
Moore, Kathleen N.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (30) : 3528 - +
[8] Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial)
Fagotti, Anna
Vizzielli, Giuseppe
Ferrandina, Gabriella
Fanfani, Francesco
Gallotta, Valerio
Chiantera, Vito
Costantini, Barbara
Margariti, Pasquale Alessandro
Alletti, Salvatore Gueli
Cosentino, Francesco
Tortorella, Lucia
Scambia, Giovanni
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[9] Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.
Ferron, Gwenael
De Rauglaudre, Gaetan
Chevalier, Annick
Combe, Pierre
Joly, Florence
Lortholary, Alain
Raban, Nadia
Hamizi, Salima
Malaurie, Emmanuelle
Kaminsky, Marie-Christine
Pautier, Patricia
Meunier, Jerome
Alexandre, Jerome
Berton-Rigaud, Dominique
Floquet, Anne
Venat-Bouvet, Laurence
Favier, Laure
Dohollou, Nadine
Dubot, Coraline
Ray-Coquard, Isabelle Laure
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[10] Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 Mutations
George, Joshy
Alsop, Kathryn
Etemadmoghadam, Dariush
Hondow, Heather
Mikeska, Thomas
Dobrovic, Alexander
DeFazio, Anna
Smyth, Gordon K.
Levine, Douglas A.
Mitchell, Gillian
Bowtell, David D.
[J]. CLINICAL CANCER RESEARCH, 2013, 19 (13) : 3474 - 3484

← 1 2 3 →